Forget Antibodies. Use Aptamers!™ Forget Antibodies. Use Aptamers!™
R&D Inquiry Quote
Contact Us

Apta-Index™: Osteopontin (2-O-Me OPN-R3) (ID# 371)

Back to Search Results

Osteopontin (2-O-Me OPN-R3) (ID# 371)

Osteopontin (2-O-Me OPN-R3)
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
2'-O-Me-RNA Human Osteopontin Protein 18 nM (reported value) Binding Buffer: PBS (137 nM NaCl, 27 nM KCl, 100 nM Na2HPO4, 2 nM K2HPO4, pH 7.4) N/A If the oligo is a known aptamer sequence: For binding studies, perform a refolding program to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding. This aptamer is a modified version of OPN-R3 in which the 2'-F-RNA residues have been replaced with 2'-O-Me RNA. The binding affinity was found to be identical to OPN-R3. The modified aptamer was used in vivo on xenograft mice and was found to decrease tumor growth and metastasis.
5'-mCprGprGpmCpmCprApmCprAprGprAp rApmUprGprAprAprAprAprApmCpmCp mUpmCprApmUpmCprGprApmUprGpmUp mUprGpmCprApmUprAprGpmUpmUprGp -3'
40 13079.35 g/mole 402900.00 L/(mole·cm) 45.00% 2.48 32.46

Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.

Z Mi et al. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Molecular Therapy 17(2009): 153-161

Have your aptamer oligo synthesized by one of our AFFILIATES

Community Feedback

Forget Antibodies. Use Aptamers!™ Forget Antibodies. Use Aptamers!™